Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Share Price | £16.6373 |
| Volume | 47 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing reports an acquisition of 47 ordinary shares by Mr. R G Connor, President of Global Manufacturing & Supply. This transaction resulted from the re-investment of dividends paid to shareholders on July 14, 2016, under the Company's ShareReward Plan. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- The transaction involves Mr. R G Connor, a senior executive (President, Global Manufacturing & Supply).
- The acquisition was not a direct purchase but a dividend re-investment via the ShareReward Plan.
- The transaction volume is minimal (47 shares) and reflects standard plan mechanics rather than a strategic market move.
- The share price at the time of transaction was £16.6373.